Ac-DEVD-AMC

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ac-DEVD-AMC
• 英文别名: N-acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin；(4S)-4-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2S)-1-[[(2S)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
• 化学式: C₃₀H₃₇N₅O₁₃
• 分子量: 675.649
• InChiKey: ALZSTTDFHZHSCA-RNVDEAKXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  48
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  284
• 氢给体数：
  8
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  Ac-DEVD-AMC 在 recombinant human caspase-3 作用下， 以 二甲基亚砜 为溶剂， 生成 7-氨基-4-甲基香豆素
  参考文献：
  名称：

  Organic Azide Inhibitors of Cysteine Proteases

  摘要：

  Cysteine proteases are crucial regulatory enzymes in human physiology and disease. Inhibitors are usually designed with reactive electrophiles to covalently bond to the catalytic cysteinyl sulfur, and consequently they also indiscriminately interact with biological thiolates and other nucleophiles, leading to toxic side effects in vivo. Here we describe an alternative to using reactive electrophiles, demonstrating the use of a much less reactive azidomethylene substituent (-CH2-N3) that confers potent inhibition of cysteine proteases. This new approach resulted in potent, reversible, competitive inhibitors of caspase-1 (IC50 < 10 nM), with significant advantages over aldehydes such as high stability in vitro to thiols (10 mM dithiothreitol (pH 7.2), 20 mM glutathione (pH 7.2, 9, 11)) and aqueous media, as well as some highly desirable druglike features. It was also demonstrated that azides can be incorporated into inhibitors of other caspases (e.g. 3, 8) and cathepsins (e.g. K, S, B), indicating the versatility of this valuable new approach to cysteine protease inhibition.

  DOI：

  10.1021/ja0637649

文献信息

• Substituted benzimidazoles and imidazo-[4,5]-pyridines
  申请人：——

  公开号：US20040214857A1

  公开（公告）日：2004-10-28

  2-Aryl substituted benzimidazoles and imidazo[4,5]pyridines are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.

  2-芳基取代苯并咪唑和咪唑[4,5]吡啶被披露为Cds1的抑制剂，并在癌症治疗中作为化疗或放疗的辅助剂。
• ANTIOXIDANT COMPOUND HAVING ANTI ATHEROSCLEROTIC EFFECT AND PREPARATION THEREOF
  申请人：Council of Scientific and Industrial Research

  公开号：US20160244470A1

  公开（公告）日：2016-08-25

  The present invention relates to an antioxidant compound having anti atherosclerotic effect and preparation thereof. The present invention more particularly relates to the synthesis of TPP+ coupled esculetin (mitochondria-targeted esculetin [Mito-Esc]) followed by the biological evaluation of Mito-Esc for its ability to attenuate Angiotensin-II-induced atherosclerosis in apolipoproteinE knockout (ApoE −/− ) mice along with the endothelial cell age-delaying effects of Mito-Esc.

  本发明涉及一种具有抗动脉粥样硬化作用的抗氧化剂化合物及其制备。本发明更特别涉及TPP+偶联异丁香素的合成（线粒体靶向异丁香素[Mito-Esc]），随后对Mito-Esc进行生物评价，以评估其减轻血管紧张素II诱导的载脂蛋白E缺陷（ApoE−/−）小鼠动脉粥样硬化的能力，以及Mito-Esc对内皮细胞延缓衰老的影响。
• Aryl-substituted benzimidazole and imidazopyridine ethers
  申请人：Breitenbucher Guy J.

  公开号：US20060004039A1

  公开（公告）日：2006-01-05

  Aryl substituted benzimidazole and imidazo[4,5]pyridine ethers are described as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.

  芳基取代的苯并咪唑和咪唑[4,5]吡啶醚被描述为Cds1的抑制剂，并在癌症治疗中作为化疗或放疗的辅助剂。
• [EN] CASPASES AND APOPTOSIS<br/>[FR] CASPASES ET APOPTOSE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2001022966A1

  公开（公告）日：2001-04-05

  The present invention is to the novel compounds of Formula (I), their pharmaceutical compositions, and to the novel inhibition of caspases for use in the treatment of apoptosis, and disease states caused by excessive or inappropriate cell death.

  本发明涉及式（I）的新化合物、它们的制药组合物，以及用于治疗细胞凋亡和由过度或不适当的细胞死亡引起的疾病状态的新的半胱天冬酶抑制剂。
• USE OF CARBONIC ANHYDRASE II FOR PRODUCING A DRUG
  申请人：Consejo Superior de Investigaciones Cientificas (CSIC)

  公开号：EP2452949A1

  公开（公告）日：2012-05-16

  The present invention relates to the field of biomedicine. Specifically, the present invention relates to the use of carbonic anhydrase II for producing a drug for preventing and/or treating damage caused by ischemia, ischemia followed by reperfusion or a toxin, acute failure or rejection of an organ transplant, preferably of a kidney. In a preferred embodiment, the toxin is cisplatin.

  本发明涉及生物医学领域。具体而言，本发明涉及利用碳酸酐酶 II 生产药物，用于预防和/或治疗由缺血、缺血后再灌注或毒素、急性衰竭或器官移植（最好是肾脏移植）排斥反应引起的损伤。在一个优选的实施方案中，毒素是顺铂。